In this episode of What's up Wednesday, obesity medicine specialist Karli Burridge discusses the outcomes of the recently published study: Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial by Timothy Garvey et al., published in Nature Medicine October 10, 2022.The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (behavioral intervention) for long-term treatment of adults with obesity, or preobesity with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104.Listen in to hear the outcomes of the study and how you can incorporate this latest scienc einto your clinical practice!Find the study HERESupport the Treat and Reduce Obesity Act HERESupport the showThe Gaining Health Podcast will release a new episode every Wednesday, alternating between interviews with experts and "What's Up Wednesday" scientific updates.For a roadmap for developing an obesity program, editable forms and templates, patient education materials, and more, check out Gaining Health If you are loving this podcast, please consider supporting us on Patreon